@article {MAKITA4353, author = {KAORI MAKITA and TAKASHI KAMIGAKI and SACHIKO OKADA and ERIKO MATSUDA and HIROSHI IBE and ERI OGUMA and KEIKO NAITOH and RISHU TAKIMOTO and SHIGENORI GOTO}, title = {Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy}, volume = {38}, number = {7}, pages = {4353--4360}, year = {2018}, doi = {10.21873/anticanres.12736}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. Materials and Methods: The correlation between overall survival (OS) and various factors including sex, age, performance status (PS), distant metastasis, chemotherapy, radiotherapy, and type of immune-cell therapy were evaluated by univariate and multivariate analyses. Results: The median OS of advanced or recurrent pancreatic cancer was 5.8 months, and the prognosis was improved in pancreatic cancer patients who received immune-cell therapy with PS scores of 0-1 [hazard risk (HR)=0.56; 95\% confidence interval (CI)=0.46-0.68; p\<0.0001], chemotherapy (HR=0.68; 95\%CI=0.54-0.87; p=0.002), or radiotherapy (HR=0.76; 95\%CI=0.63-0.93; p=0.006). Multivariate analysis demonstrated that distant metastasis indicated a poor prognosis for pancreatic cancer patients that were administered immune-cell therapy (HR=1.62; 95\%CI=1.37-1.93; p\<0.0001). Additionally, the combined immune-cell therapy with αβ T cell and dendritic cell (DC) vaccine provided a survival benefit in advanced or recurrent pancreatic cancer patients (HR=0.69; 95\%CI=0.57-0.83; p\<0.0001). Conclusion: A survival benefit could be potentially obtained with better PS by the combination of αβ T cell therapy, DC vaccine therapy, and chemotherapy at an early stage in pancreatic cancer.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/7/4353}, eprint = {https://ar.iiarjournals.org/content/38/7/4353.full.pdf}, journal = {Anticancer Research} }